T-cell immunity to the joining region of p210BCR-ABL protein
about
Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell developmentCancer genetics and tumor antigens: time for a combined view?BCR-ABL as a target for novel therapeutic interventions.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.IL2 treatment for cancer: from biology to gene therapyCalcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cellsIL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.Therapeutic use of Aldara in chronic myeloid leukemia.Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.Current status and future prospects of peptide-based cancer vaccines.Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.Mutated Ras peptides as vaccines in immunotherapy of cancer.Chronic myeloid leukemia as an immunological target.Graft-versus-leukemia effect and its clinical implications.Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response.Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.Tumor recognition by the cellular immune system: new aspects of tumor immunology.The biological therapy of acute and chronic leukemia.A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice.Stem cell origins of leukaemia and curability
P2860
Q34049333-07527C4C-89D8-47B4-BE92-E0C1DEBFFBEAQ34495646-320AFDCE-D398-4036-B068-7ABB4136FDB4Q34568971-636BB646-B3CD-4445-9E3D-7416DF83AC10Q35166848-E544AC56-3B75-45CB-AFDE-3D7E02378D92Q35565971-23F448C2-EC3C-4CD3-8EFD-5ED7BB1F1742Q35620629-0F9D4673-4FFB-40AC-AAB7-1C4CB5B42AF4Q35950374-6A9C39A3-51CA-4095-911A-5E42F64A6D03Q36367821-FB7B1B7B-7F1C-4F9E-A334-5B7C1C298B97Q36718548-7991BF78-FBBC-4FBB-9C96-9033E1ACF5E9Q36914397-A6006730-0B93-48D1-9C5E-C6B92DB2A330Q37724672-99D31E3C-2D48-4CE7-8FF4-FDE7C336DB48Q38780728-2ED83A44-6F52-4E40-8143-2CC005A863ABQ39804661-E3B17301-4A59-4284-A665-43E4E23F0339Q40507908-994275C7-AE2E-4E5C-A8F9-A3F03F94A20BQ40548689-B4A88727-50C9-4A52-8C9E-8D9BA26E6F9CQ40712555-8FE9B493-FCA4-4813-935C-B1522730CEB9Q40846439-59976663-6380-4BFE-BAE3-913210211F11Q40916271-0411B514-67A8-40A9-9AEA-C8742A7D71AFQ40920988-9A9D19DB-FA91-4E01-BB8A-DDB4407D89F5Q41079581-DF36A6F3-E804-43D2-9382-85769DB55542Q41169564-BE66BE6F-D78D-4D41-8BBD-B9FFC66D05C1Q41455911-AA50217B-DC15-428C-ABB5-C1030ABFA1A4Q41552414-E7216380-1D60-41CF-BEC6-68D9CE42AC3FQ41848394-DEC27FEF-EA7B-4FE4-9587-E43C16273186Q42050130-5BCB08F5-396C-4202-AE82-FB5D06A2D8ED
P2860
T-cell immunity to the joining region of p210BCR-ABL protein
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
T-cell immunity to the joining region of p210BCR-ABL protein
@en
type
label
T-cell immunity to the joining region of p210BCR-ABL protein
@en
prefLabel
T-cell immunity to the joining region of p210BCR-ABL protein
@en
P2093
P2860
P356
P1476
T-cell immunity to the joining region of p210BCR-ABL protein
@en
P2093
P2860
P304
P356
10.1073/PNAS.89.4.1468
P407
P577
1992-02-01T00:00:00Z